https://www.selleckchem.com/pr....oducts/pexidartinib-
2%] and Class B = 19 [26.8%]). Sixty patients completed the study (mean age 61.7 ± 8.8 years, males 40 [66.6%], and CTP Class A = 45 [75.0%] and Class-B = 15 [25.0%]). Two patients dropped out due to adverse events. Nine patients were lost to follow up. Patients given melatonin had a significantly lower PSQI and ESS compared to both pretreatment ( 0.001) and postplacebo scores ( 0.001). Incidence of adverse events was similar (two each of abdominal pain, one each of headache, one each of dizziness) in both group
Like
Comment
Share
